Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your genes prevent bad drug reactions? new study aims to find out

NCT ID NCT06219720

Knowledge-focused Sponsor: Texas A&M University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study at Texas A&M University is testing whether genetic testing can help reduce harmful side effects in people taking five or more medications. Researchers will use a special computer dashboard to analyze each patient's drug list and genetic profile, then suggest safer options. The study involves 50 adults aged 45 and older and focuses on how well the system works in a real clinic setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pharmacogenomic testing and clinical decision-support dashboard
What this could lead to
If successful, this could help doctors personalize medication choices to reduce side effects and hospital visits for people taking multiple drugs.
What could go wrong
This is a very small pilot study (50 people) focused on feasibility, not on proving a treatment works. The results may not apply to larger or different populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study plans to recruit at most 50 volunteers from the Texas A\&M affiliated community health family medicine program.

Ages

45 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs * Ability to give and comprehend the consent process. * Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination. * All genders. * Age 45 and over Exclusion Criteria: * Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded. * Admitted to hospice. * Patient has ever been diagnosed with Hepatitis B or C. * Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \>10, ALT or AST \>100U/L or an AST/ALT ratio \>2 * Patients taking imidazole antifungal medication. * Declines to participate or interact with staff/share their medical status. * A diagnosis of Alzheimer's disease * Pregnant patients will be excluded * Unable/unwilling to consent. * Unable to verbally communicate and comprehend English/Spanish language.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug reaction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Interprofessional Pharmacogenomics (IPGx) Clinic

    RECRUITING

    Bryan, Texas, 77802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.